Skip to main content

Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.

New study outlines the safety profile of a novel, naturally-occurring methylxanthine compound (paraxanthine) in foods and provides a direct head-to-head comparison between paraxanthine Px and caffeine.

Wellbeing Digital Sciences Inc. (“Wellbeing” or the “Company”) (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announced today that its wholly owned subsidiary KGK Science Inc. (“KGK”), completed preclinical safety studies for Rarebird Coffee (“Rarebird”), a manufacturer and own label distributor of coffee crafted with paraxanthine (Px), a caffeine replacement.

KGK has authored a manuscript entitled “Paraxanthine safety and comparison to caffeine,” which was published in the journal “Frontiers in Toxicology on February 2, 2023. Paraxanthine, the predominant metabolite of caffeine, is found in small amounts in coffee and other plants. Our bodies routinely convert caffeine into Px, but the pharmacological effects resulting from this metabolism, have not been well characterized. Preclinical studies of safety, using Rarebird Coffee’s Px ingredients, were conducted as a first step prior to market entry. Px has been proposed as a safer alternative to caffeine for use in foods and beverages, and the comparison study to caffeine lends support this premise.

The extensive battery of safety tests suggested a lack of genetic toxicity and mutagenicity. Repeat-dose safety studies indicated a larger No-Observed-Adverse-Effect-Level (NOAEL) for Px in comparison to caffeine, suggesting an improved safety profile for Px. These findings further the scientific understanding of the safety profile for Px, a subject that has largely been ignored despite the prevalence of caffeine-containing food products in the marketplace.

“This study represents an important first step to both further our understanding of caffeine safety and highlight the use of Px as a potential caffeine replacement” says Najla Guthrie, CEO of Wellbeing Digital and KGK.

“The safety profile of Px, in comparison to caffeine, is apparent in this study. It is imperative that consumers understand how caffeine is metabolized and to know whether those metabolites are more or less safe than caffeine. The head-to-head comparison in this study suggests paraxanthine Px has an improved safety profile over caffeine, and one of our goals is to increase consumer awareness of Px as an innovative caffeine replacement,” says Jeffrey Dietrich, founder and CEO of Rarebird, Inc.

ABOUT Rarebird, Inc

Rarebird is a coffee company whose goal is to turn people’s coffee routines into wellness rituals. Founded in 2020, Rarebird produces Px coffee, a ground coffee that contains paraxanthine instead of caffeine.


Subsidiary of Wellbeing Digital Sciences, KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 25,000 participants in its database and collected 10 million data points. For additional information, please visit


Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development. For additional information, please visit

On behalf of:

Najla Guthrie

Chief Executive Officer


Notice Regarding Forward-Looking Information:

This news release contains forward-looking statements including but not limited to statements regarding the Company’s business, assets or investments, as well other statements that are not historical facts. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, investor interest in the business and prospects of the Company.

The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made, by third parties in respect of the matters discussed above.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.